It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma Patients
The intention with HBI0101 CART is to follow the chimeric antigen receptor T-cells (CART) approach, as for approved products, but target the B cell maturation antigen (BCMA) rather than the CD19 antigen targeted by KYMRIAHTM (tisagenlecleucel) and YESCARTATM (axicabtagene ciloleucel).
Importantly, successful results from at least three clinical trials of a BCMA targeted CAR T therapy were published (Zhao 2018, Brundo 2018, Raje 2019), with excellent results obtained for relapsed or refractory multiple myeloma (MM) patients, that validate the approach. The CAR vector employed for HBI0101 CART is almost identical to the vector employed for the clinical study reported by Raje 2019, therefore, a strong therapeutic response is expected also for HBI0101 CART together with a similar manageable safety profile
Condition | Dose Escalation and Safety |
---|---|
Treatment | CART BCMA |
Clinical Study Identifier | NCT04720313 |
Sponsor | Hadassah Medical Organization |
Last Modified on | 3 February 2021 |
,
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.